Nature Communications (Sep 2022)
A small molecule antagonist of SMN disrupts the interaction between SMN and RNAP II
- Yanli Liu,
- Aman Iqbal,
- Weiguo Li,
- Zuyao Ni,
- Yalong Wang,
- Jurupula Ramprasad,
- Karan Joshua Abraham,
- Mengmeng Zhang,
- Dorothy Yanling Zhao,
- Su Qin,
- Peter Loppnau,
- Honglv Jiang,
- Xinghua Guo,
- Peter J. Brown,
- Xuechu Zhen,
- Guoqiang Xu,
- Karim Mekhail,
- Xingyue Ji,
- Mark T. Bedford,
- Jack F. Greenblatt,
- Jinrong Min
Affiliations
- Yanli Liu
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University
- Aman Iqbal
- Structural Genomics Consortium, University of Toronto
- Weiguo Li
- Hubei Key Laboratory of Genetic Regulation and Integrative Biology, School of Life Sciences, Central China Normal University
- Zuyao Ni
- Donnelly Centre, University of Toronto
- Yalong Wang
- Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center
- Jurupula Ramprasad
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University
- Karan Joshua Abraham
- Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto
- Mengmeng Zhang
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University
- Dorothy Yanling Zhao
- Donnelly Centre, University of Toronto
- Su Qin
- Structural Genomics Consortium, University of Toronto
- Peter Loppnau
- Structural Genomics Consortium, University of Toronto
- Honglv Jiang
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University
- Xinghua Guo
- Donnelly Centre, University of Toronto
- Peter J. Brown
- Structural Genomics Consortium, University of Toronto
- Xuechu Zhen
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University
- Guoqiang Xu
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University
- Karim Mekhail
- Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto
- Xingyue Ji
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University
- Mark T. Bedford
- Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center
- Jack F. Greenblatt
- Donnelly Centre, University of Toronto
- Jinrong Min
- Hubei Key Laboratory of Genetic Regulation and Integrative Biology, School of Life Sciences, Central China Normal University
- DOI
- https://doi.org/10.1038/s41467-022-33229-5
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
The SMN protein recognizes symmetric dimethylarginine by its Tudor domain, and SMN deficiency leads to spinal muscular atrophy. Here, Liu et al. discover a small molecule that binds to the SMN Tudor domain and disrupts the interaction between SMN and RNA Polymerase II.
